Amgen scraps experimental weight loss pill, moves forward with injection [CNBC]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNBC
The announcement is a setback for Amgen, which is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly , which some analysts say could be worth $100 billion by the end of the decade. But the company has other opportunities to capture a slice of the market. “Given the profile we've seen with [the oral drug], we will not pursue further development. Instead, in obesity, we're differentially investing in MariTide and a number of preclinical assets,” Jay Bradner, Amgen's chief scientific officer, said during an earnings call Thursday. Amgen is developing an injectable obesity treatment called MariTide, which is an ongoing midstage trial in obese or overweight adults without diabetes. The company will release initial data from that study later this year and said it is working with regulators to plan a late-stage trial. Amgen is planning a stage two trial on the drug in diabetes treatment as well. Amgen also has other drugs
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative To Wegovy [Forbes]Forbes
- Hims & Hers Adds Weight-Loss Injections, Stock Soars [Yahoo! Finance]Yahoo! Finance
- Wellness Platform Hims & Hers Health Adds GLP-1 Injections For Weight Loss, Stock Soars [Yahoo! Finance]Yahoo! Finance
- Genetics may determine who responds well to Wegovy: report [Seeking Alpha]Seeking Alpha
- Genetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness, Study Reveals [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/17/24 - Form 6-K
- 5/17/24 - Form SD
- 5/15/24 - Form 6-K
- NVO's page on the SEC website